keyword
MENU ▼
Read by QxMD icon Read
search

SLE therapy

keyword
https://www.readbyqxmd.com/read/28099213/hydroxychloroquine-induced-erythema-multiforme
#1
Nour Abou Assalie, Robert Durcan, Laura Durcan, Michelle A Petri
Hydroxychloroquine is the cornerstone of medical therapy in systemic lupus erythematosus (SLE). We report a case of erythema multiforme in association with this medication in a 25-year-old white woman with SLE. We provide a detailed review of the reported cases in the literature of hydroxychloroquine-induced severe cutaneous adverse reactions. To our knowledge, this is the first reported case of hydroxychloroquine-induced erythema multiforme in the setting of SLE.
January 18, 2017: Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases
https://www.readbyqxmd.com/read/28097391/-tapering-and-termination-of-immunosuppressive-therapy-systemic-lupus-erythematosus
#2
REVIEW
M Aringer, N Leuchten, R Fischer-Betz
Similar to patients with other rheumatic diseases, patients with systemic lupus erythematosus (SLE) nowadays can also have the desire to terminate immunosuppressive and immunomodulatory medications. In order to provide appropriate advice to patients, the two main issues are the risk of severe adverse events under long-term therapy with any drug and the perceived risk of a flare, in particular of severe flares. The risks of long-term therapy vary greatly between drugs, ranging from severe unacceptable risks with cyclophosphamide and higher dose glucocorticoids to low risks usually outweighed by long-term benefits with hydroxychloroquine...
January 17, 2017: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/28089979/quality-of-care-for-systemic-lupus-erythematosus-mind-the-knowledge-gap
#3
Vera Golder, Eric F Morand, Alberta Y Hoi
Systemic lupus erythematosus (SLE) is a prototypical chronic multiorgan autoimmune disorder that can lead to significant burden of disease and loss of life expectancy. The disease burden is the result of a complex interplay between genetic, biologic, socioeconomic, and health system variables affecting the individual. Recent advances in biological understanding of SLE are yet to translate to transformative therapies, and genetic and socioeconomic variables are not readily amenable to intervention. In contrast, healthcare quality, a variable readily amenable to change, has been inadequately addressed in SLE, despite evidence in other chronic diseases that quality of care is strongly associated with patient outcomes...
January 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/28089248/triggering-receptor-expressed-on-myeloid-cells-1-trem-1-deficiency-augments-baff-production-to-promote-lupus-progression
#4
Chi-Jui Liu, Chang-Youh Tsai, Ssu-Hsuan Chiang, Shye-Jye Tang, Nien-Jung Chen, Tak Wah Mak, Guang-Huan Sun, Kuang-Hui Sun
Sensing of nucleic acids by pattern recognition receptors is the key for the initiation and development of systemic lupus erythematosus (SLE). Triggering receptor expressed on myeloid cells-1 (TREM-1) is a novel innate immune receptor, which can amplify Toll-like receptor (TLR)-induced inflammatory responses. Although patients with lupus exhibit increased serum levels of soluble TREM-1 (sTREM-1), the role of TREM-1 in SLE remains unknown. In current study, we found serum sTREM-1 levels were significantly increased in lupus patients and positively correlated with disease activity...
January 11, 2017: Journal of Autoimmunity
https://www.readbyqxmd.com/read/28079801/acute-necrotizing-retinal-vasculitis-as-onset-of-systemic-lupus-erythematosus-a-case-report
#5
Simeon Monov, Ruska Hristova, Rositza Dacheva, Reni Toncheva, Russka Shumnalieva, Viara Shoumnalieva-Ivanova, Daniela Monova
RATIONALE: Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by autoantibody production, complement activation, and deposition of immune complexes in tissues and organs. SLE can involve any region of the visual system. Although ocular manifestations are not part of the classification criteria for SLE, they can be observed in up to one-third of the patients with SLE. They are rarely reported at the time of disease onset. Retinal vasculitis is usually associated with active generalized disease...
January 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28066821/evaluation-of-receptor-ligand-mechanisms-of-dual-targeted-particles-to-an-inflamed-endothelium
#6
Catherine A Fromen, Margaret B Fish, Anthony Zimmerman, Reheman Adili, Michael Holinstat, Omolola Eniola-Adefeso
Vascular-targeted carriers (VTCs) are designed as leukocyte mimics, decorated with ligands that target leukocyte adhesion molecules (LAMs) and facilitate adhesion to diseased endothelium. VTCs require different design considerations than other targeted particle therapies; adhesion of VTCs in regions with dynamic blood flow requires multiple ligand-receptor (LR) pairs that provide particle adhesion and disease specificity. Despite the ultimate goal of leukocyte mimicry, the specificity of multiple LAM-targeted VTCs remains poorly understood, especially in physiological environments...
March 2016: Bioeng Transl Med
https://www.readbyqxmd.com/read/28059023/the-short-term-efficacy-of-bortezomib-combined-with-glucocorticoids-for-the-treatment-of-refractory-lupus-nephritis
#7
H Zhang, Z Liu, L Huang, J Hou, M Zhou, X Huang, W Hu, Z Liu
Objective The treatment of refractory lupus nephritis (LN) remains challenging for clinicians because these patients either do not respond to conventional therapy or relapse during the maintenance treatment period. The aim of this study was to investigate the efficacy and safety of bortezomib combined with glucocorticoids in refractory lupus patients. Methodology Five refractory LN patients aged 21 to 43 years (four females and one male) with biopsy-proven diagnosis (four with type IV and one with type V+IV) were recruited...
January 1, 2017: Lupus
https://www.readbyqxmd.com/read/28053320/direct-measurement-of-b-cell-receptor-repertoire-s-composition-and-variation-in-systemic-lupus-erythematosus
#8
S Liu, X L Hou, W G Sui, Q J Lu, Y L Hu, Y Dai
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that is known to be associated with polyclonal B-cell hyper-reactivity. B-cell receptor (BCR) has a central role in B-cell development, activation, survival and apoptosis, and thus is a critical component of the regulation of both protective and autoreactive B cells. In this study, we applied multiplex PCR and Illumina high-throughput sequencing to study the composition and variation of the BCRs in peripheral blood mononuclear cells from SLE patients and healthy donors (NC)...
January 5, 2017: Genes and Immunity
https://www.readbyqxmd.com/read/28039419/cumulative-immunosuppressant-exposure-is-associated-with-diversified-cancer-risk-among-14-832-patients-with-systemic-lupus-erythematosus-a-nested-case-control-study
#9
Chung-Yuan Hsu, Ming-Shyan Lin, Yu-Jih Su, Tien-Tsai Cheng, Yu-Sheng Lin, Ying-Chou Chen, Wen-Chan Chiu, Tien-Hsing Chen
OBJECTIVES: Immunosuppressive therapy is necessary to alter the natural course of SLE. However, immunosuppressant-related cancer risk is a major concern. The aim of this study was to determine whether immunosuppressant use is associated with cancer risk in SLE. METHODS: We designed a retrospective nested case-control study within an SLE population based on the National Health Insurance Research Database in Taiwan. We screened 14 842 patients with SLE from 2001 to 2013 and compared patients with SLE complicated by later cancer with patients with SLE but without cancer...
December 30, 2016: Rheumatology
https://www.readbyqxmd.com/read/28013208/it-hasn-t-gone-away-the-problem-of-glucocorticoid-use-in-lupus-remains
#10
Diane Apostolopoulos, Eric F Morand
The treatment of SLE remains complex, and management is constrained by a lack of safe, effective, targeted therapies. Physicians, also, are constrained by a lack of evidence-based approaches with existing agents, including glucocorticoids, utilized in the majority of patients. While Cushingoid side effects of glucocorticoids are widely recognized, emerging literature now suggests that glucocorticoid use actually contributes to harmful outcomes in SLE, over and above these effects. These studies provide a compelling case for a re-evaluation of the long-term use of glucocorticoids in SLE, focusing on minimizing glucocorticoid exposure as part of the strategy to improve long-term outcomes...
December 24, 2016: Rheumatology
https://www.readbyqxmd.com/read/28005299/polymeric-selectin-ligands-mimicking-complex-carbohydrates-from-selectin-binders-to-modifiers-of-macrophage-migration
#11
Kai E Moog, Matthias Barz, Matthias Bartneck, Figen Beceren-Braun, Nicole Mohr, Zhuojun Wu, Lydia Braun, Jens Dernedde, Elisa A Liehn, Frank Tacke, Twan Lammers, Horst Kunz, Rudolf Zentel
Novel polymeric cell adhesion inhibitors were developed in which the selectin tetrasaccharide sialyl-Lewis(X) (SLe(X) ) is multivalently presented on a biocompatible poly(2-hydroxypropyl)methacrylamide (PHPMA) backbone either alone (P1) or in combination with O-sulfated tyramine side chains (P2). For comparison, corresponding polymeric glycomimetics were prepared in which the crucial "single carbohydrate" substructures fucose, galactose, and sialic acid side chains were randomly linked to the PHPMA backbone (P3 or P4 (O-sulfated tyramine))...
December 22, 2016: Angewandte Chemie
https://www.readbyqxmd.com/read/28003329/early-onset-juvenile-sle-associated-with-a-novel-mutation-in-protein-kinase-c-%C3%AE
#12
Sira Nanthapisal, Ebun Omoyinmi, Claire Murphy, Ariane Standing, Michael Eisenhut, Despina Eleftheriou, Paul A Brogan
Juvenile systemic lupus erythematosus (jSLE) is rare before 5 years of age. Monogenic causes are suspected in cases of very early onset jSLE particularly in the context of a family history and/or consanguinity. We performed whole-exome sequencing and homozygosity mapping in the siblings presented with early-onset jSLE. A novel homozygous missense mutation in protein kinase C delta (c.1294G>T; p.Gly432Trp) was identified in both patients. One patient showed a marked clinical response and resolution inflammation with rituximab therapy...
January 2017: Pediatrics
https://www.readbyqxmd.com/read/28000522/targeting-the-interferon-pathway-with-sifalimumab-for-the-treatment-of-systemic-lupus-erythematosus
#13
Warren Greth, Gabriel J Robbie, Philip Brohawn, Micki Hultquist, Bing Yao
Dysregulation of the type I interferon (IFN) system is associated with various immunologic diseases, such as systemic lupus erythematosus (SLE). Targeting this dysregulation presents an attractive approach for SLE therapy. Sifalimumab, a fully human immunoglobulin G1 κ monoclonal antibody that binds to and neutralizes most IFN-α subtypes, has been recently evaluated in a Phase IIb study in patients with moderate to severe SLE. Insights gained from earlier studies were used to inform design of the Phase IIb study, to provide a more comprehensive evaluation of sifalimumab...
January 2017: Immunotherapy
https://www.readbyqxmd.com/read/28000010/two-cases-demonstrating-thalidomide-s-efficacy-in-refractory-lupus-nephritis
#14
REVIEW
Rita Raturi, Avani A Patel, John D Carter
Renal involvement in systemic lupus erythematosus (SLE) is common and has been associated with an increased risk of mortality [1]. Early diagnosis is imperative to control proteinuria and prevent the progression to end-stage renal disease. Standard induction therapies include cyclophosphamide (CYC) and mycophenolate mofetil (MMF); however, it has been estimated that approximately 30% of patients are refractory to these standard treatments after 1 year [2]. We present two cases of patients diagnosed with lupus nephritis (LN) who demonstrated persistent proteinuria while on standard treatments that markedly improved after addition of thalidomide (THD)...
December 20, 2016: Clinical Rheumatology
https://www.readbyqxmd.com/read/27992696/longitudinal-patterns-of-response-to-standard-of-care-therapy-for-systemic-lupus-erythematosus-implications-for-clinical-trial-design
#15
Mimi Kim, Joan Merrill, Kenneth Kalunian, Bevra Hahn, Anita Roach, Peter Izmirly
OBJECTIVE: To evaluate longitudinal patterns of response to standard of care (SOC) therapy in clinical trials for systemic lupus erythematosus (SLE) and identify characteristics that differentiate non-responders from persistent responders. METHODS: Data were obtained from the Collective Data Analysis Initiative of the Lupus Foundation of America on 147 patients treated with placebo plus SOC in two 52-week Phase II/III trials in moderately-to-severely active SLE patients without acute nephritis...
December 19, 2016: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/27990444/association-of-serum-cxcl13-with-intrarenal-ectopic-lymphoid-tissue-formation-in-lupus-nephritis
#16
De Ning He, Wen Li Chen, Kang Xia Long, Xiao Zhang, Guang Fu Dong
Aims. To assess the concentrations of serum CXCL13 and intrarenal ectopic lymphoid tissue (ELT) profiles and their correlation in the patients with lupus nephritis (LN). Methods. Serum CXCL13 levels were measured using enzyme-linked immunosorbent assays (ELISA). The expression of CD3, CD20, and CD21 in renal biopsy specimens was tested using immunohistochemical methods. Results. Serum CXCL13 levels were significantly higher in the LN group than those in the SLE group without LN and also in the type III and IV LN patients than in type V LN patients...
2016: Journal of Immunology Research
https://www.readbyqxmd.com/read/27989533/the-use-of-direct-oral-anticoagulants-in-56-patients-with-antiphospholipid-syndrome
#17
Katarzyna Malec, Tadeusz Góralczyk, Anetta Undas
INTRODUCTION: Antiphospholipid syndrome (APS) is a common acquired thrombophilia associated with a high thrombotic risk, in which vitamin K antagonists (VKA) represent the mainstay of therapy. Case series involving up to 35 patients with APS suggested limited efficacy and safety of direct oral anticoagulants (DOACs). MATERIAL AND METHODS: In the prospective case series we followed 56 consecutive patients with APS (44 women and 12 men, aged from 22 to 64years), including 33 (60%) associated with systemic lupus erythematosus (SLE) and 16 (28...
December 14, 2016: Thrombosis Research
https://www.readbyqxmd.com/read/27974963/bullous-systemic-lupus-erythematosus-and-lupus-nephritis-in-a-young-girl
#18
Tooba Momen, Yahya Madihi
Bullous systemic lupus erythematosus (BSLE) is an autoimmune blistering disease occurring in patients with systemic lupus erythematosus (SLE). It is a rare disease, especially in children. A 14-year-old girl initially presented with fatigue, generalized vesiculobullous skin lesions, and ulcers over the hard palate and oral mucosa. Clinical investigations revealed hematuria and proteinuria, a high erythrocyte sedimentation rate and titer of antinuclear antibody, and anti-double-stranded DNA. Skin biopsy findings were suggestive of BSLE...
November 2016: Oman Medical Journal
https://www.readbyqxmd.com/read/27974236/integrative-therapy-decreases-the-risk-of-lupus-nephritis-in-patients-with-systemic-lupus-erythematosus-a-population-based-retrospective-cohort-study
#19
Ching-Mao Chang, Po-Chang Wu, Jen-Huai Chiang, Yau-Huei Wei, Fang-Pey Chen, Tzeng-Ji Chen, Tai-Long Pan, Hung-Rong Yen, Hen-Hong Chang
ETHNOPHARMACOLOGICAL RELEVANCE: Evidence on alleviating the risk of lupus nephritis by integrative therapy with conventional medicine (CM) and herbal medicine (HM) had not been addressed. AIM OF THE STUDY: We investigated the integrative effect associated the risk by a retrospective Systemic Lupus Erythematosus (SLE) cohort from Taiwan National Health Insurance Research Database (NHIRD). MATERIALS AND METHODS: SLE patients with a catastrophic illness certificate (CIC) were retrospectively enrolled from the SLE cohort of the Taiwan NHIRD between 1997 and 2011...
January 20, 2017: Journal of Ethnopharmacology
https://www.readbyqxmd.com/read/27933432/lupus-pathobiology-based-on-genomics
#20
REVIEW
Mohammad Saeed
Systemic lupus erythematosus (SLE) is an autoimmune disorder with complex genetic underpinnings. This review attempts to assemble the myriad of genomic findings to build a clearer picture of the pathobiology of SLE to serve as a guide for therapeutics. Over 100 genes are now known for SLE, and several more penetrant ones have led to the emergence of more defined lupus phenotypes. Also discussed here are the targeted therapies that have come up on the horizon and the specific biologic mechanisms of more traditional therapies which have only recently been explored...
January 2017: Immunogenetics
keyword
keyword
57199
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"